Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
Posted:
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
S-PRO has become a member of SwissICT, the largest professional association for the Information and Communications Technology industry in Switzerland. Read the full article here.
Registration for 2024 MedConnect North event is now open and places have been filling up - reserve your place today & don't miss out!
Date: 26 September
Time: 9am - 4.30pm
Register here.